



The Commissioner is authorized to charge any fees associated with this communication to Deposit Account No. 15-0615 for any matter in connection with this response, including any fee for extension of time, which may be required.

Respectfully submitted,

Date: September 10, 2001

By:   
Gregory Glotta  
Reg. No. 32,028

ONYX Pharmaceuticals, Inc.  
3031 Research Drive  
Richmond, California 94806  
Telephone (510) 262-8710  
Facsimile (510) 222-9758



RECEIVED

SEP 20 2001

TECH CENTER 1600/2900

APPENDIX A

Amendments showing modifications to patent application.

- 2/3. An adenoviral vector as described in claim 1 or 15 wherein said deletion of said E1b region genes comprises p19, 55K, and pIX.
- 6/8. An recombinant adenoviral vector as described in claim 1 or 15 wherein said heterologous gene encodes a protein selected from the group consisting of tumor necrosis factor alpha, interferon gamma, an interleukin, a cell suicide protein, cytosine deaminase, thymidine kinase and mip-3.
- 7/9. Cells comprising said adenoviral vectors of claim 1 or 15.
- 10/11. A method for treating a mammal having a neoplastic condition in need of said treatment, comprising administering to said mammal a therapeutically effective dose of said adenoviral vectors of claims 1, 5, [or] 6 or 15.

Please add the following claim.

- 15. A recombinant adenoviral vector comprising a deletion of E1b region gene(s), but retaining the E1b promoter, and substituting for said E1b region gene(s) a heterologous gene that is operable linked to said E1b promoter. --